The role of topical simvastatin on bone regeneration: A systematic review

Montero, Javier; Manzano, Guillermo; Albaladejo, Alberto

doi:10.4317/jced.51415

Cited by 21 publications

(18 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Masuzaki et al gave a single injection of fluvastatin impregnated microspheres to rats with tibial titanium implants, this demonstrated enhanced bone growth and bone contact at 14 days as demonstrated by staining and microscopy around the implant and was accompanied by an increased bending strength, as measured by extraction of the femur following implantation at 2 or 4 weeks after surgery followed by three point bending with a universal testing machine 33 . Similar studies have reported encouraging results with simvastatin coated implants, scaffolds and biomaterials 34,35 . Topical application of statins may therefore confer the potential beneficial osteogenic effects outlined previously but Osseointegration generally occurs within 3 months of primary arthroplasty 36,37 .…”

Section: Statins and Osseointegration Of Prosthetic Implants And Bonesupporting

confidence: 69%

Statins, Bone Biology and Revision Arthroplasty: Review of Clinical and Experimental Evidence

Sorial

Anjum

Cook

et al. 2020

Preprint

View full text Add to dashboard Cite

Osteoarthritis is a painful, disabling condition which is increasing in prevalence as a result of an ageing population. With no recognised disease limiting therapeutics, arthroplasty of the hip and knee is the most common and effective treatment for lower limb osteoarthritis, however lower limb arthroplasty has a finite life-span and a proportion of patients will require revision arthroplasty. With increasing life expectancy and the proportion of younger (<65 years) patients undergoing arthroplasty, the demand for revision arthroplasty after implant failure is also set to increase. Statins are cholesterol modulating drugs widely used for cardiovascular risk reduction, which have been noted to have pleiotropic effects including potentially influencing arthroplasty survival. Epidemiological and experimental research have demonstrated that there may be a biological and population-wide effect of statins in reducing the risk of revision arthroplasty. This work summarises the current breadth of evidence for this phenomenon including in vitro, in vivo and epidemiological research.

show abstract

Section: Statins and Osseointegration Of Prosthetic Implants And Bonesupporting

confidence: 69%

Statins, Bone Biology and Revision Arthroplasty: Review of Clinical and Experimental Evidence

Sorial

Anjum

Cook

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…12 Besides its lipid-lowering effects, simvastatin can also modulate bone regeneration process at both molecular and cellular levels by participating in activation of osteoblast and inhibition of osteoclast. 13 Moreover, simvastatin could not only inhibit 3-hydroxy-3-methylglutarylcoenzyme A reductase and the mevalonic acid pathway but also increase the osteoprotegerin expression to antagonize osteoclasts. 14 Nylestriol, a derivative of long-acting estriol and a kind of lente estrogen, was synthesized in China in 1984.…”

Section: Introductionmentioning

confidence: 99%

Effects of Simvastatin and Combination of Simvastatin and Nylestriol on Bone Metabolism in Ovariectomized Rats

Li¹,

Lin²,

Xie³

et al. 2016

American Journal of Therapeutics

View full text Add to dashboard Cite

We aim to compare the effects of simvastatin and combination of simvastatin and nylestriol on bone metabolism in ovariectomized (OVX) rats. Fifty healthy Wistar female rats were randomly allocated into 5 groups: sham + saline group (group A), OVX + saline group (group B), OVX + simvastatin (5 mg·kg·d) (group C), OVX + nylestriol (0.01 mg·kg·d) (group D), and OVX + simvastatin (3 mg·kg·d) + nylestriol (0.005 mg·kg·d) (group E). All mice were orally administrated with saline or medicine dissolved in saline for 10 weeks. Body weight of rats before and after the experiment was measured. Twenty-four hours after the experiment, calcium (Ca), creatinine (Cr), and hydroxyproline in urine were detected. Serum levels of osteocalcin (bone Gla-protein, BGP) and alkaline phosphatase (ALP) were measured. Bone mineral density was detected and trabecular bone was observed after the isolation of femur and tibia. Remarkably decreased serum BGP and increased serum ALP levels were detected in group B compared with those in group A. However, notably increased serum BGP and decreased serum ALP levels were found in groups C, D, and E compared with those in group B; femoral and tibial bone mineral density decreased in group B compared with that in group A, but increased in groups C, D, and E compared with that in group B. Simvastatin and combination of simvastatin and nylestriol promote formation of new bone, increase bone density, and improve bone microstructure damage in OVX rats.

show abstract

“…1,2 This class of drug can inhibit HMG-CoA reductase from turning into mevalonic acid, and is widely used for hyperlipidemia treatment. 1,2 Several researchers have demonstrated that SV has pleiotropic effects, including anti-inflammatory action, 2,3 induces angiogenesis and improves the function of endothelial cells, 4,5,6,7,8 as well as enhancing the synthesis and mineralization of bone 9,10,11,12,13 and dentin 6,14,15,16,17 matrices. The pathway for SV mediating osteo/odontogenic differentiation is not fully known.…”

Section: Introductionmentioning

confidence: 99%

Biostimulatory effects of simvastatin on MDPC-23 odontoblast-like cells

et al. 2017

View full text Add to dashboard Cite

The aim of this study was to evaluate the bioactivity and cytocompatibility of simvastatin (SV) applied to MDPC-23 odontoblast-like cells. For this purpose, MDPC-23 cells were seeded in 96-well plates and submitted to treatments with 0.01 or 0.1 µM of SV for 24 h, 72 h or continuously throughout the experimental protocol. The negative control group (NC) was maintained in DMEM. Cell viability (MTT), ALP activity (thymolphthalein monophosphate), and mineralized matrix deposition (alizarin red) were analyzed at several time points. The data were submitted to ANOVA and Tukey's test (α = 0.05). Although cell viability was observed in the groups treated with SV, these groups did not differ from the NC up to 7 days. There was a reduction in cell viability for the groups treated with 0.1 µM of SV for 72 h, and submitted to continuous mode after 14 days. A significant increase in ALP activity occurred in the group treated with 0.01 µM of SV for 24 h, compared with the NC; however, only the group treated with 0.1 µM of SV in continuous mode reduced the ALP activity, in comparison with the NC. After 14 days, only continuous treatment with 0.1 µM of SV did not differ from NC, whereas the other experimental groups showed increased mineralized matrix deposition. Thus, it was concluded that low concentrations of simvastatin were bioactive and cytocompatible when applied for short periods to cultured MDPC-23 odontoblast-like cells.

show abstract

The role of topical simvastatin on bone regeneration: A systematic review

Cited by 21 publications

References 36 publications

Statins, Bone Biology and Revision Arthroplasty: Review of Clinical and Experimental Evidence

Statins, Bone Biology and Revision Arthroplasty: Review of Clinical and Experimental Evidence

Effects of Simvastatin and Combination of Simvastatin and Nylestriol on Bone Metabolism in Ovariectomized Rats

Biostimulatory effects of simvastatin on MDPC-23 odontoblast-like cells

Contact Info

Product

Resources

About